Swedish Orphan Biovitrum
220,4 SEK -0,81 %1 investor følger denne virksomhed
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Omsætning
18,79 mia.
EBIT %
20,29 %
P/E
24,71
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
SOBI
Daglig lav / høj pris
220 / 222,2
SEK
Markedsværdi
68,28 mia. SEK
Aktieomsætning
32,2 mio. SEK
Volumen
146 t
Finanskalender
Delårsrapport
18.07.2023
Delårsrapport
26.10.2023
Årsrapport
08.02.2024
Viser Alle indholdstyper